Tevogen Bio Highlights Most Recent Insider Ownership of 74%; Management Maintains Conviction in the Company’s Mission
Tevogen Bio Holdings Inc. (Nasdaq: TVGN) has announced that company insiders, including executive officers and board members, currently hold approximately 74% of outstanding shares as of April 7, 2025. This significant insider ownership demonstrates management's confidence in the company's progress and potential.
The healthcare company operates in two main areas: immunotherapy through Tevogen Bio, which develops off-the-shelf, genetically unmodified T cell therapeutics for infectious diseases and cancers, and artificial intelligence through Tevogen.AI, focused on enhancing drug discovery, clinical trial efficiency, and patient access. The company operates solely in the U.S. and maintains a tariff-insensitive position amid current market volatility.
CEO Dr. Ryan Saadi highlighted that insiders have only sold shares to satisfy tax obligations related to restricted stock vesting, further emphasizing their commitment to the company's mission of redefining the future of medicine.
Tevogen Bio Holdings Inc. (Nasdaq: TVGN) ha annunciato che i membri interni dell'azienda, inclusi funzionari esecutivi e membri del consiglio, detengono attualmente circa il 74% delle azioni in circolazione al 7 aprile 2025. Questa significativa proprietà interna dimostra la fiducia della direzione nei progressi e nel potenziale dell'azienda.
L'azienda sanitaria opera in due aree principali: immunoterapia attraverso Tevogen Bio, che sviluppa terapie con cellule T geneticamente non modificate pronte all'uso per malattie infettive e tumori, e intelligenza artificiale attraverso Tevogen.AI, focalizzata sul miglioramento della scoperta di farmaci, sull'efficienza delle sperimentazioni cliniche e sull'accesso dei pazienti. L'azienda opera esclusivamente negli Stati Uniti e mantiene una posizione non sensibile ai dazi in mezzo all'attuale volatilità del mercato.
Il CEO Dr. Ryan Saadi ha sottolineato che i membri interni hanno venduto azioni solo per soddisfare obblighi fiscali legati all'acquisizione di azioni vincolate, sottolineando ulteriormente il loro impegno nella missione dell'azienda di ridefinire il futuro della medicina.
Tevogen Bio Holdings Inc. (Nasdaq: TVGN) ha anunciado que los miembros internos de la empresa, incluidos los funcionarios ejecutivos y los miembros de la junta, poseen actualmente aproximadamente el 74% de las acciones en circulación a partir del 7 de abril de 2025. Esta significativa propiedad interna demuestra la confianza de la dirección en el progreso y el potencial de la empresa.
La empresa de atención médica opera en dos áreas principales: inmunoterapia a través de Tevogen Bio, que desarrolla terapias con células T genéticamente no modificadas listas para usar para enfermedades infecciosas y cánceres, y inteligencia artificial a través de Tevogen.AI, enfocada en mejorar el descubrimiento de fármacos, la eficiencia de los ensayos clínicos y el acceso de los pacientes. La empresa opera exclusivamente en los EE. UU. y mantiene una posición insensible a aranceles en medio de la actual volatilidad del mercado.
El CEO Dr. Ryan Saadi destacó que los miembros internos solo han vendido acciones para satisfacer obligaciones fiscales relacionadas con la adquisición de acciones restringidas, enfatizando aún más su compromiso con la misión de la empresa de redefinir el futuro de la medicina.
Tevogen Bio Holdings Inc. (Nasdaq: TVGN)는 2025년 4월 7일 기준으로 경영진 및 이사회를 포함한 회사 내부자들이 현재 약 74%의 발행 주식을 보유하고 있다고 발표했습니다. 이러한 중요한 내부자 소유는 회사의 발전과 잠재력에 대한 경영진의 신뢰를 보여줍니다.
이 헬스케어 회사는 두 가지 주요 분야에서 운영됩니다: 면역요법을 통해 Tevogen Bio는 감염병 및 암을 위한 즉시 사용 가능한 유전자 변형이 없는 T세포 치료제를 개발하고, 인공지능을 통해 Tevogen.AI는 약물 발견, 임상 시험 효율성 및 환자 접근성을 향상시키는 데 중점을 두고 있습니다. 이 회사는 미국에서만 운영되며 현재 시장의 변동성 속에서 세금에 민감하지 않은 입장을 유지하고 있습니다.
CEO Dr. Ryan Saadi는 내부자들이 제한된 주식의 귀속과 관련된 세금 의무를 충족하기 위해서만 주식을 판매했음을 강조하며, 회사의 의학의 미래를 재정의하려는 사명에 대한 그들의 헌신을 더욱 강조했습니다.
Tevogen Bio Holdings Inc. (Nasdaq: TVGN) a annoncé que les initiés de l'entreprise, y compris les dirigeants et les membres du conseil d'administration, détiennent actuellement environ 74% des actions en circulation au 7 avril 2025. Cette propriété significative des initiés démontre la confiance de la direction dans les progrès et le potentiel de l'entreprise.
L'entreprise de santé opère dans deux domaines principaux : immunothérapie à travers Tevogen Bio, qui développe des thérapies à base de cellules T génétiquement non modifiées prêtes à l'emploi pour les maladies infectieuses et les cancers, et intelligence artificielle à travers Tevogen.AI, axée sur l'amélioration de la découverte de médicaments, de l'efficacité des essais cliniques et de l'accès des patients. L'entreprise opère exclusivement aux États-Unis et maintient une position insensible aux tarifs en période de volatilité du marché actuelle.
Le PDG Dr. Ryan Saadi a souligné que les initiés n'ont vendu des actions que pour satisfaire des obligations fiscales liées à l'acquisition d'actions restreintes, soulignant ainsi leur engagement envers la mission de l'entreprise de redéfinir l'avenir de la médecine.
Tevogen Bio Holdings Inc. (Nasdaq: TVGN) hat angekündigt, dass Unternehmensinsider, einschließlich der Führungskräfte und Vorstandsmitglieder, derzeit etwa 74% der ausstehenden Aktien zum 7. April 2025 halten. Dieser signifikante Insiderbesitz zeigt das Vertrauen des Managements in den Fortschritt und das Potenzial des Unternehmens.
Das Gesundheitsunternehmen ist in zwei Hauptbereichen tätig: Immuntherapie durch Tevogen Bio, das sofort einsatzbereite, genetisch unveränderte T-Zell-Therapeutika für Infektionskrankheiten und Krebs entwickelt, und künstliche Intelligenz durch Tevogen.AI, das sich auf die Verbesserung der Medikamentenentdeckung, die Effizienz klinischer Studien und den Zugang der Patienten konzentriert. Das Unternehmen ist ausschließlich in den USA tätig und behält eine zollunempfindliche Position inmitten der aktuellen Marktschwankungen.
CEO Dr. Ryan Saadi hob hervor, dass Insider Aktien nur verkauft haben, um steuerliche Verpflichtungen im Zusammenhang mit der Vesting von beschränkten Aktien zu erfüllen, was ihr Engagement für die Mission des Unternehmens, die Zukunft der Medizin neu zu definieren, weiter betont.
- High insider ownership (74%) indicates strong management confidence
- Tariff-insensitive business model due to U.S.-only operations
- Diversified business model combining immunotherapy and AI technology
- Company may need to raise additional capital to execute business plan
- operating history poses execution risks
- Faces regulatory risks and potential delays in clinical trials
WARREN, N.J., April 07, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a healthcare company with dedicated efforts in immunotherapy and artificial intelligence, is unified by a commitment to advancing patient-centric solutions. The Company’s clinical-stage immunotherapy effort, Tevogen Bio, focuses on the development of off-the-shelf, genetically unmodified T cell therapeutics for infectious diseases and cancers. Its artificial intelligence effort, Tevogen.AI, aims to advance innovation in drug discovery, clinical trial efficiency, and patient access. Together, these efforts represent the foundational pillars of Tevogen’s broader vision to redefine the future of medicine.
With this in mind, Tevogen today highlights the significant number of shares held by executive officers and members of the board of directors of the Company, emphasizing their conviction of the mission and progress of Tevogen. The insiders own approximately
“Our collective confidence in the Company’s current progress and vast potential is reflected in the ownership by insiders,” said Tevogen CEO Dr. Ryan Saadi. “Additionally, given the current market volatility, we note the Company solely operates in the U.S., and to some degree, is tariff-insensitive.”
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: expectations regarding the healthcare and biopharmaceutical industries; Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer; Tevogen’s plans to expand its efforts in artificial intelligence; Tevogen’s ability to develop additional product candidates; Tevogen’s use of funds from the grant; and the potential receipt of additional future grants. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the outcome of any legal proceedings that may be instituted against Tevogen; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; the ability to develop, license or acquire new therapeutics; that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K and subsequent filings with the SEC.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
FAQ
What percentage of Tevogen Bio (TVGN) shares are owned by insiders as of April 2025?
What are the two main business segments of Tevogen Bio (TVGN)?
Why have Tevogen Bio (TVGN) insiders sold shares?
How is Tevogen Bio (TVGN) positioned regarding market volatility and tariffs?
